WO2000030587A3 - INHIBITEURS DE L'ACTIVATION DE NF-λB, ET LEURS UTILISATIONS PHARMACEUTIQUES - Google Patents

INHIBITEURS DE L'ACTIVATION DE NF-λB, ET LEURS UTILISATIONS PHARMACEUTIQUES Download PDF

Info

Publication number
WO2000030587A3
WO2000030587A3 PCT/FR1999/002897 FR9902897W WO0030587A3 WO 2000030587 A3 WO2000030587 A3 WO 2000030587A3 FR 9902897 W FR9902897 W FR 9902897W WO 0030587 A3 WO0030587 A3 WO 0030587A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical uses
activation inhibitors
inhibitors
treating
factor
Prior art date
Application number
PCT/FR1999/002897
Other languages
English (en)
Other versions
WO2000030587A2 (fr
Inventor
Francois Hirsch
Astrid Haeffner
Original Assignee
Centre Nat Rech Scient
Francois Hirsch
Astrid Haeffner
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Nat Rech Scient, Francois Hirsch, Astrid Haeffner filed Critical Centre Nat Rech Scient
Priority to JP2000583472A priority Critical patent/JP2002537224A/ja
Priority to EP99958229A priority patent/EP1131088A2/fr
Priority to US09/856,796 priority patent/US6914046B1/en
Priority to AU15643/00A priority patent/AU1564300A/en
Priority to CA002351733A priority patent/CA2351733A1/fr
Publication of WO2000030587A2 publication Critical patent/WO2000030587A2/fr
Publication of WO2000030587A3 publication Critical patent/WO2000030587A3/fr
Priority to US11/144,889 priority patent/US20050272654A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH] (Somatotropin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention a pour objet l'utilisation d'inhibiteurs du facteur nucléaire NF-λB, dans le cadre du traitement de cancers, et plus particulièrement d'hémopathies malignes ou de tumeurs solides, ainsi que les produits contenant un composé inhibiteur de l'activation de NF-λB et une molécule cytotoxique susceptible d'activer le facteur NF-λB, en tant que préparation de combinaison pour une utilisation simultanée, séparée, ou étalée dans le temps pour le traitement desdites pathologies.
PCT/FR1999/002897 1998-11-25 1999-11-24 INHIBITEURS DE L'ACTIVATION DE NF-λB, ET LEURS UTILISATIONS PHARMACEUTIQUES WO2000030587A2 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
JP2000583472A JP2002537224A (ja) 1998-11-25 1999-11-24 ＮＦ−κＢ活性化阻害剤及びそれらの医薬としての使用
EP99958229A EP1131088A2 (fr) 1998-11-25 1999-11-24 INHIBITEURS DE L'ACTIVATION DE NF-$g(k)B, ET LEURS UTILISATIONS PHARMACEUTIQUES
US09/856,796 US6914046B1 (en) 1998-11-25 1999-11-24 NF-κB activation inhibitors, and their pharmaceutical uses
AU15643/00A AU1564300A (en) 1998-11-25 1999-11-24 NF-kB activation inhibitors, and their pharmaceutical uses
CA002351733A CA2351733A1 (fr) 1998-11-25 1999-11-24 Inhibiteurs de l'activation de nf-kb, et leurs utilisations pharmaceutiques
US11/144,889 US20050272654A1 (en) 1998-11-25 2005-06-06 NF-kappaB activation inhibitors, and their pharmaceutical uses

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR98/14858 1998-11-25
FR9814858A FR2786104B1 (fr) 1998-11-25 1998-11-25 Inhibiteurs de l'activation de nf-kb, et leurs utilisations pharmaceutiques

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/144,889 Division US20050272654A1 (en) 1998-11-25 2005-06-06 NF-kappaB activation inhibitors, and their pharmaceutical uses

Publications (2)

Publication Number Publication Date
WO2000030587A2 WO2000030587A2 (fr) 2000-06-02
WO2000030587A3 true WO2000030587A3 (fr) 2000-09-14

Family

ID=9533184

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR1999/002897 WO2000030587A2 (fr) 1998-11-25 1999-11-24 INHIBITEURS DE L'ACTIVATION DE NF-λB, ET LEURS UTILISATIONS PHARMACEUTIQUES

Country Status (7)

Country Link
US (2) US6914046B1 (fr)
EP (1) EP1131088A2 (fr)
JP (1) JP2002537224A (fr)
AU (1) AU1564300A (fr)
CA (1) CA2351733A1 (fr)
FR (1) FR2786104B1 (fr)
WO (1) WO2000030587A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003090681A2 (fr) * 2002-04-24 2003-11-06 Research Development Foundation Effets synergetiques des inhibiteurs du facteur nf-kb de transcription nucleaire et d'agents anti-cancereux
CN1674881A (zh) * 2002-06-26 2005-09-28 学校法人庆应义塾 含NF－κB抑制剂的医药组合物
GB0228441D0 (en) * 2002-12-05 2003-01-08 Ares Trading Sa Splice variant
KR20050097962A (ko) * 2003-02-14 2005-10-10 각고호우징 게이오기주크 의약 조성물
ES2967701T3 (es) * 2013-03-15 2024-05-03 Translate Bio Inc Mejora sinergística de la entrega de ácidos nucleicos mediante formulaciones mezcladas

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999006040A1 (fr) * 1997-08-04 1999-02-11 Berry Christopher J Procede pour traiter les maladies a l'aide d'un tocotrienol, et d'un acide alpha-lipoique ou des derives ou un ester de ces derniers

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL97779A (en) * 1990-04-10 2000-01-31 Genentech Inc Compositions for cytoprotection against radiation and chemotherapy injury or risk thereof
US20020052309A1 (en) * 1996-09-11 2002-05-02 Athanasius A. Anagnostou Method of treating endothelial injury
US6831057B2 (en) * 1997-10-28 2004-12-14 The University Of North Carolina At Chapel Hill Use of NF-κB inhibition in combination therapy for cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999006040A1 (fr) * 1997-08-04 1999-02-11 Berry Christopher J Procede pour traiter les maladies a l'aide d'un tocotrienol, et d'un acide alpha-lipoique ou des derives ou un ester de ces derniers

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DIGICAYLIOGLU, MURAT ET AL: "Neuroprotection from nitric oxide by erythropoietin ( EPO ) is mediated by NFkappaB.", SOCIETY FOR NEUROSCIENCE ABSTRACTS, (1998) VOL. 24, NO. 1-2, PP. 1792. MEETING INFO.: 28TH ANNUAL MEETING OF THE SOCIETY FOR NEUROSCIENCE, PART 2 LOS ANGELES, CALIFORNIA, USA NOVEMBER 7-12, 1998 SOCIETY FOR NEUROSCIENCE., XP002116163 *
HAEFFNER A ET AL: "Growth hormone prevents human monocytic cells from Fas-mediated apoptosis by up-regulating Bcl-2 expression.", EUROPEAN JOURNAL OF IMMUNOLOGY, (1999 JAN) 29 (1) 334-44., XP000907591 *
HAEFFNER A ET AL: "Inhibitory effect of growth hormone on TNF-alpha secretion and nuclear factor -kappaB translocation in lipopolysaccharide-stimulated human monocytes.", JOURNAL OF IMMUNOLOGY, (1997 FEB 1) 158 (3) 1310-4., XP002116164 *
WANG C Y ET AL: "TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB [see comments].", SCIENCE, (1996 NOV 1) 274 (5288) 784-7., XP002139552 *

Also Published As

Publication number Publication date
EP1131088A2 (fr) 2001-09-12
CA2351733A1 (fr) 2000-06-02
JP2002537224A (ja) 2002-11-05
AU1564300A (en) 2000-06-13
FR2786104A1 (fr) 2000-05-26
US20050272654A1 (en) 2005-12-08
US6914046B1 (en) 2005-07-05
FR2786104B1 (fr) 2002-12-27
WO2000030587A2 (fr) 2000-06-02

Similar Documents

Publication Publication Date Title
PL354540A1 (en) Drugs for the treatment of malignant tumours
IL148288A0 (en) Indolealkanol ester and indolealkylamide derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
ATE312080T1 (de) 2-chinolonen enthaltende arzneimittel
IL159022A0 (en) Hv protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis
GEP20084461B (en) New derivative of 3,3- diphenyl-propylamine
WO2001066098A3 (fr) Utilisations therapeutiques des mediateurs ppar
IL112969A0 (en) Pharmaceutical composition comprising t-cell actiVator for the treatment of cancer
MXPA01012184A (es) Composicion dietetica o farmaceutica para utilizarse en la prevencion o tratamiento de la hiperoxaluria.
WO2002028832A3 (fr) Compositions de diindolylmethane et de diindolylmethane c-substitue et procedes de traitement de cancers multiples
HK1024177A1 (en) Cytotoxic amino sugar and related sugar derivatives of indolopyrrolocarbazoles
CA2386775A1 (fr) Medicaments de traitement de tumeurs malignes
HUP0203108A3 (en) Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis
AU9342898A (en) Contrasting agent for infarct and necrosis imaging
AU2508597A (en) Drug for the treatment of tumours
AU2002226030A1 (en) Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
HUP0204006A3 (en) Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis
CA2152771A1 (fr) Derives 7-o-ether de taxane
AU5892399A (en) 1, 2, 4-triazole-3-thione compounds
IL160148A0 (en) Pharmaceutical compositions comprising polysaccharide conjugates for inhibiting the metastasis or preventing the recurrence of malignant tumor
AU4811200A (en) Multiple feed powder splitter
WO2000030587A3 (fr) INHIBITEURS DE L'ACTIVATION DE NF-λB, ET LEURS UTILISATIONS PHARMACEUTIQUES
WO2001012607A3 (fr) Compositions pharmaceutiques comprenant des 4-quinolones pour le traitement des cancers
HUP0300772A3 (en) Medicament for the immunotherapy of malignant tumours
AU2001214116A1 (en) Novel paclitaxel derivatives for the treatment of cancer
WO1999056697A3 (fr) Composition pharmaceutique

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref country code: AU

Ref document number: 2000 15643

Kind code of ref document: A

Format of ref document f/p: F

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2351733

Country of ref document: CA

Ref country code: CA

Ref document number: 2351733

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1999958229

Country of ref document: EP

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 583472

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 09856796

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1999958229

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1999958229

Country of ref document: EP